# ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas

> **NCT05079022** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Adenocarcinoma of Lung

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT05079022
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10
- **Primary completion:** 2023-03
- **Final completion:** 2024-09
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2021-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079022, "ctDNA-MRD Based Adjuvant Targeted Therapy for EGFR Positive Stage I Lung Adenocarcinomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05079022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*